EISAI TO PRESENT LATEST DATA ON FYCOMPA® (PERAMPANEL) AT 69TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the latest data on its in-house developed AMPA receptor antagonist Fycompa® (perampanel hydrate, “perampanel”) will be presented at the 69th American Epilepsy Society (AES) Annual Meeting to be held from December 4 to 8 in Philadelphia in the United States.

For this year’s AES meeting, poster presentations will be given on 22 abstracts with highlights including additional and pooled analyses on the results of global Phase III clinical studies on primary generalized tonic-clonic (PGTC) seizures in patients with generalized epilepsy (Study 332) and on partial-onset epilepsy (Study 304, Study 305, Study 306), as well as the results of a Phase III clinical study on partial-onset epilepsy conducted in Asia including Japan. Furthermore, the overall results of Study 332, Study 304, and Study 306 were published in the major scientific journal Neurology, while the overall results of Study 305 were published in the specialist epilepsy journal Epilepsia.

Perampanel is a first-in-class antiepileptic drug (AED) discovered and developed by Eisai. With epileptic seizures being primarily mediated by the neurotransmitter glutamate, the agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at postsynaptic AMPA receptors. Perampanel is approved in more than 45 countries including in Europe and North America, as well as countries in Asia such as Malaysia, Thailand, Philippines and South Korea, as an adjunctive treatment for partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy aged 12 years and older, and has been launched in more than 25 countries around the world under the brand name Fycompa. Furthermore, perampanel was approved for an indication expansion regarding the adjunctive therapy of PGTC seizures in patients from 12 years of age with generalized epilepsy in the United States and Europe in June 2015. Meanwhile, Eisai submitted a regulatory application for perampanel in Japan covering both PGTC seizures and partial-onset seizures (with or without secondarily generalized seizures) based primarily on Study 332 and Study 335 in July 2015.

Epilepsy affects nearly 1 million people in Japan, 2.9 million people in the United States, 6 million people in Europe, and more than 60 million people worldwide. Furthermore, over half of the people with epilepsy worldwide are estimated to live in Asia. As approximately 30% of patients with epilepsy are unable to sufficiently control their seizures with currently available AEDs, this is a disease with significant unmet medical needs. Eisai considers epilepsy a therapeutic area of focus and by providing multiple treatment options in addition to perampanel as part of an extensive epilepsy product portfolio, Eisai seeks to make continued contributions to address the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

**Major Poster Presentations:**

<table>
<thead>
<tr>
<th>Abstract number</th>
<th>Abstract title</th>
</tr>
</thead>
</table>
| Abstract number: #1.184  
Saturday December 5  
Poster presentation: 12:00-18:00  
Poster discussion: 12:00-14:00 | Effect of Adjunctive Perampanel in Pediatric Subjects With Epilepsy: Preliminary Safety and Efficacy Results From Study 232 |
| Abstract number: #1.187  
Saturday December 5  
Poster presentation: 12:00-18:00  
Poster discussion: 12:00-14:00 | Pharmacokinetics of Perampanel in Children with Epilepsy Aged 2 to12 Years |
| Abstract number: #1.188  
Saturday December 5  
Poster presentation: 12:00-18:00  
Poster discussion: 12:00-14:00 | Efficacy of Perampanel by Baseline Seizure Frequency in Patients with Partial Seizures (Phase III Double-Blind Studies) |
| Abstract number: #1.189  
Saturday December 5  
Poster presentation: 12:00-18:00  
Poster discussion: 12:00-14:00 | Suicidality Events in Patients With Primary Generalized Tonic-Clonic Seizures (PGTCS): A Review of Study 332 |
| Abstract number: #1.190  
Saturday December 5  
Poster presentation: 12:00-18:00  
Poster discussion: 12:00-14:00 | Psychiatric and Behavioral Events with Perampanel in Patients with Primary Generalized Tonic-Clonic Seizures (PGTCS): Study 332 |
| Abstract number: #1.191  
Saturday December 5  
Poster presentation: 12:00-18:00  
Poster discussion: 12:00-14:00 | Subanalysis by Baseline Antiepileptic Drugs (AEDs): Results From Perampanel Study 332 in Patients With Primary Generalized Tonic-Clonic Seizures (PGTCS) |
| Abstract number: #1.192  
Saturday December 5  
Poster presentation: 12:00-18:00  
Poster discussion: 12:00-14:00 | Review of Pregnancy Events in Perampanel Clinical Studies |
| Abstract number: #1.193  
Saturday December 5  
Poster presentation: 12:00-18:00  
Poster discussion: 12:00-14:00 | Effect of Duration of Epilepsy on Adjunctive Perampanel Treatment in Patients With Drug-Resistant Partial Seizures |
| Abstract number: #1.194  
Saturday December 5  
Poster presentation: 12:00-18:00  
Poster discussion: 12:00-14:00 | Analysis of Falls in the Phase III Perampanel Study of Primary Generalized Tonic-Clonic Seizures (PGTCS) |
| Abstract number: #1.195  
Saturday December 5  
Poster presentation: 12:00-18:00  
Poster discussion: 12:00-14:00 | Clinical Laboratory Evaluation and TEAEs Related to Cardiac, Hepatic and Renal Disorders: Perampanel PGTC Phase III Study |

(continued on following page)
<table>
<thead>
<tr>
<th>Abstract number</th>
<th>Abstract title</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1.196</td>
<td>Long-Term Perampanel Treatment in Patients With Drug-Resistant Partial Seizures: ≥75% Responders and Seizure-Free Status</td>
</tr>
<tr>
<td>#1.111</td>
<td>Model-predicted relationships between perampanel plasma concentrations and efficacy for partial-onset seizures (POS) and primary generalized tonic-clonic (PGTC) seizures</td>
</tr>
<tr>
<td>#1.121</td>
<td>Protein Binding of Perampanel in Human Plasma: Does Protein-Binding Displacement Occur?</td>
</tr>
<tr>
<td>#1.124</td>
<td>Pharmacokinetics of adjunctive perampanel in patients with partial-onset seizures and primary generalized tonic-clonic (PGTC) seizures in idiopathic generalized epilepsy (IGE): pooled data from four randomized, double-blind Phase III studies</td>
</tr>
<tr>
<td>#1.335</td>
<td>Budget Impact of Perampanel for Treating Primary Generalized Tonic Clonic Seizures (PGTC) Patients in addition to existing Partial-Onset Seizures (POS) Patients in the US</td>
</tr>
<tr>
<td>#1.374</td>
<td>Caregiver Burden: An Under-Recognized Aspect of Epilepsy Care</td>
</tr>
<tr>
<td>#2.239</td>
<td>Effect of perampanel on neuroprotection in the lithium-pilocarpine rat model of status epilepticus</td>
</tr>
<tr>
<td>#2.250</td>
<td>Efficacy and tolerability of perampanel in patients (pts) with secondarily generalized (SG) or primary generalized tonic-clonic seizures (PGTC): a pooled analysis of four randomized, Phase III studies</td>
</tr>
<tr>
<td>#2.263</td>
<td>Efficacy and safety of adjunctive perampanel (PER) in adolescents with inadequately controlled partial-onset seizures (POS): randomized, double-blind and open-label extension (OLE) study</td>
</tr>
<tr>
<td>#3.256</td>
<td>A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of perampanel as adjunctive therapy in patients with refractory partial-onset seizures from the Asia-Pacific region</td>
</tr>
<tr>
<td>#3.260</td>
<td>Long-term cognitive effects of adjunctive perampanel (PER) in adolescents for treatment of partial-onset seizures (POS): randomized, double-blind and open-label extension (OLE) study</td>
</tr>
<tr>
<td>#3.262</td>
<td>Effect of adjunctive perampanel on growth and development in adolescents with inadequately controlled partial-onset seizures (POS): randomized, double-blind and open-label extension (OLE) study</td>
</tr>
</tbody>
</table>